Why Merck Is Poised to Keep Poppin'
With that in mind, let's take a closer look at Merck and see what CAPS investors are saying about the stock right now.
Whitehouse Station, N.J. (1891)
Chairman/CEO Kenneth Frazier
Return on Equity (average, past 3 years)
$16.0 billion / $20.8 billion
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 93% of the 2,924 members who have rated Merck believe the stock will outperform the S&P 500 going forward.
The pharmacy business is not going anyplace. The company has opportunely announced an enormous buyback plan, recently including $5B worth of stock from Goldman Sachs. ... Downside is protected somewhat by a dividend yield closer to 4% than 3%. Merck has to deal with patent expirations on products, but so do all its competitors. Its pipeline is robust, however.
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, The Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more click here to claim your copy today.
The article Why Merck Is Poised to Keep Poppin' originally appeared on Fool.com.Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.